The cellular uptake of antisense oligonucleotid of E6 mRNA into cervical cancer cells by DOPE-modified hydroxyapatite nanoparticles


1 Department of Medical Genetic, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

2 Research and Clinical Centre for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

3 Department of Laboratory Sciences, Faculty of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran



Although several chemical and physical methods for gene delivery have been introduced, their cytotoxicity, non-specific immune responses and the lack of biodegradability remain the main issues. In this study, hydroxyapatite nanoparticles (NPs) and 1,2-dioleoyl-sn-glycero-3-phosphoethanol​amine (DOPE)-modified hydroxyapatite NPs was coated with antisense oligonucleotide of E6 mRNA, and their uptakes into the cervical cancer cell line were evaluated.  
Materials and Methods: 
Calcium nitrate and diammonium phosphate were used for the synthesis of the hydroxyapatite nanoparticle. Thus, they were coated with polyethylene glycol (PEG), DOPE and antisense oligonucleotide of E6 mRNA using a cross-linker. Then, hydroxyapatite NPs and DOPE-modified hydroxyapatite NPs were incubated 48 hours with cervical cancer cells and their uptakes were evaluated by fluorescent microscopy.  
The hydroxyapatite NPs had different shapes and some agglomeration with average size of 100 nm. The results showed DOPE-modified hydroxyapatite NPs had higher uptake than hydroxyapatite NPs (P<0.05).  
Hydroxyapatite NPs conjugated with DOPE are a good choice for gene delivery and silencing of viral genes in cervical cancer cells, but their efficacy should be addressed more in future studies.


1. Jiang W, Kim BY, Rutka JT, Chan WC. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol. 2008; 3(3): 145-150.

2. Mohanraj V, Chen Y. Nanoparticles - a review. Trop J Pharm Res. 2007; 5(1): 561-573.

3. Bertling WM, Gareis M, Paspaleeva V, Zimmer A, Kreuter J, Nurnberg E, et al. Use of liposomes, viral capsids, and NPs as DNA carriers. Biotechnol Appl Biochem. 1991; 13(3): 390-405.

4. Han G, Ghosh P, Rotello VM. Multi-functional gold nanoparticles for drug delivery. In: Chan WCW, editor. Bio-applications of nanoparticles. USA: Springer; 2007. p. 48-56.

5. Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev. 2009; 61(9): 721-731.

6. Yin RX, Yang DZ, Wu JZ. Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. Theranostics. 2014; 4(2): 175-200.

7. Rezwan K, Chen QZ, Blaker JJ, Boccaccini AR. Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials. 2006; 27(18): 3413-3431.

8. Kong L, Gao Y, Lu G, Gong Y, Zhao N, Zhang X. A study on the bioactivity of chitosan/nano-hydroxyapatite composite scaffolds for bone tissue engineering. Eur Polym J. 2006; 42(12): 3171-3179.

9. Zhou H, Lee J. Nanoscale hydroxyapatite particles for bone tissue engineering. Acta Biomaterialia. 2011; 7(7): 2769-2781.

10. Kim HW, Knowles JC, Kim HE. Hydroxyapatite/poly(epsilon-caprolactone) composite coatings on hydroxyapatite porous bone scaffold for drug delivery. Biomaterials. 2004; 25(7): 1279-1287.

11. Uskoković V, Uskoković DP. Nanosized hydroxyapatite and other calcium phosphates: chemistry of formation and application as drug and gene delivery agents. J Biomed Mate Res B Appl Biomater. 2011; 96(1): 152-191.

12. Shimizu K, Ito A, Honda H. Mag-seeding of rat bone marrow stromal cells into porous hydroxyapatite scaffolds for bone tissue engineering. J Biosci Bioeng. 2007; 104(3): 171-177.

13. De Oliveira MC, Rosilio V, Lesieur P, Bourgaux C, Couvreur P, Ollivon M, et al. pH-sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in excess water. Biophys Chem. 2000; 87(2): 127-137.

14. Verma IM, Somia N. Gene therapy-promises, problems and prospects. Nature. 1997; 389(6648): 239-242.

15. Lammers T, Hennink W, Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer. 2008; 99(3): 392-397.

16. Wang H, Li Y, Zuo Y, Li J, Ma S, Cheng L. Biocompatibility and osteogenesis of biomimetic nano-hydroxyapatite/polyamide composite scaffolds for bone tissue engineering. Biomaterials. 2007; 28(22): 3338-3348.

17. Olton D, Li J, Wilson ME, Rogers T, Close J, Huang L, et al. Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: influence of the synthesis parameters on transfection efficiency. Biomaterials. 2007; 28(6): 1267-1279.

18. Zhu SH, Huang BY, Zhou KC, Huang SP, Liu F, Li YM, et al. Hydroxyapatite NPs as a novel gene carrier. J Nanopart Res. 2004; 6(2): 307-311.

19. Chen Y, Yang L, Huang S, Li Z, Zhang L, He J, et al. Delivery system for DNAzymes using arginine-modified hydroxyapatite nanoparticles for therapeutic application in a nasopharyngeal carcinoma model. Int J Nanomedicine. 2013; 8: 3107-18. doi: 10.2147/IJN.S48321.

20. Navarro G, Essex S, Sawant RR, Biswas S, Nagesha D, Sridhar S, et al. Phospholipid-modified polyethylenimine-based nanopreparations for siRNA–mediated gene silencing: Implications for transfection and the role of lipid components. Nanomedicine. 2014; 10(2): 411-419.

21. Akita H, Kogure K, Moriguchi R, Nakamura Y, Higashi T, Nakamura T, et al. Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. J Control Release. 2010; 143(3): 311-317.

22. Seong K, Seo H, Ahn W, Yoo D, Cho S, Khang G, et al. Enhanced cytosolic drug delivery using fully biodegradable poly(amino oxalate) particles. J Control Release. 2011; 152(2): 257-263.

23. Lechardeur D, Verkman A, Lukacs GL. Intracellular routing of plasmid DNA during non-viral gene transfer. Adv Drug Deliv Rev. 2005; 57(5): 755-767.